Discussion will include the biosimilars currently approved and coming to market within the field of dermatology including background, nuances, and evidence.
Learning Objectives:
Review what qualifies a medication as biosimilar.
Explain the nomenclature of biosimilar medications and why they are being integrated into our health system.
Discuss key lessons learned from currently-approved biosimilar medications in the US and EU.
Identify what is next for biosimilar medications within the US.
ANCC Credits: 1
Pharmacology Credit: 1.0 | 60 mins